Oncimmune Holdings has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a cancer research organisation and its cancer hospitals have more than 1,100 therapeutic and non-therapeutic clinical trials in progress.
Under this agreement, Oncimmune will utilise its biomarker discovery engine, SeroTag, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors (CPIs) and chemotherapy used in Dana-Farber-led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events (irAEs) in response treatment. The project is scheduled to complete by the end of 2021.
Dr Adam M Hill, CEO of Oncimmune, said: “We are delighted to be partnering with such a prestigious organisation as Dana-Farber on the use of multiple CPI assets in this important oncology trial and leveraging the power of our autoantibody biomarker profiling technology. As autoantibodies continue to be recognised as a key biomarker class that aid in the understanding of interactions between cancer and the immune system, the ImmunoINSIGHTS platform is becoming increasingly instrumental in studies for a wide range of cancer indications and therapy classes.”
